Medical Research Stock Performance Review -- Exact Sciences, DexCom, and PAREXEL

NEW YORK, September 13, 2017 /PRNewswire/ --

If you want a Stock Review on EXAS, DXCM, or PRXL then come over to http://dailystocktracker.com/register/ and sign up for your free customized report. As access to health care expands around the world, the need for diagnostic and research laboratory services will also increase. Growth in the industry is impacted by aging populations and rising demand for preventive care and personalized medical treatments. For today, DailyStockTracker.com has initiated coverage on four equities in the Medical Laboratories and Research space: Exact Sciences Corp. (NASDAQ: EXAS), DexCom Inc. (NASDAQ: DXCM), and PAREXEL International Corp. (NASDAQ: PRXL). These free stocks reports are currently available on DailyStockTracker.com. Simply sign up for your complimentary member access at:
http://dailystocktracker.com/register/

Exact Sciences 

Madison, Wisconsin headquartered Exact Sciences Corp.'s stock finished Tuesday's session 0.02% lower at $42.78 with a total trading volume of 1.18 million shares. Over the last month and the previous three months, the Company's shares have surged 13.29% and 32.32%, respectively. Additionally, the stock has skyrocketed 220.21% since the start of this year. Shares of the Company are trading above their 50-day and 200-day moving averages by 9.69% and 56.78%, respectively. Moreover, shares of Exact Sciences, which focuses on developing products for the early detection and prevention of various cancers in the US, have a Relative Strength Index (RSI) of 62.31. Your complete research report on EXAS can be retrieved for free at:
http://dailystocktracker.com/registration/?symbol=EXAS

DexCom 

Shares in San Diego, California headquartered DexCom Inc. rose 0.66%, ending yesterday's session at $73.61 with a total trading volume of 732,061 shares. The stock has gained 5.76% in the past month, 1.08% in the previous three months, and 23.30% on an YTD basis. The Company's shares are trading 2.56% above their 50-day moving average and 0.22% above their 200-day moving average. Moreover, shares of DexCom, which together with its subsidiaries, focuses on the design, development, and commercialization of continuous glucose monitoring systems in the US and internationally, have an RSI of 51.12.

On August 21^st, 2017, DexCom announced the publication of a new study that shows people with Type-2 diabetes on a multiple daily injection insulin therapy benefit from the use of continuous glucose monitoring. Participants in the study achieved significant A1C reduction and spent more time in range, regardless of age, education, or math ability. Sign up for your complimentary research report on DXCM at:
http://dailystocktracker.com/registration/?symbol=DXCM

PAREXEL International 

On Tuesday, Waltham, Massachusetts headquartered PAREXEL International Corp.'s stock climbed 0.11%, to close the day at $87.95. A total volume of 845,814 shares was traded. The Company's shares have advanced 0.38% in the last one month, 6.46% in the previous three months, and 33.83% on an YTD basis. The stock is trading 0.48% and 19.47% above its 50-day and 200-day moving averages, respectively. Additionally, shares of PAREXEL, which provides clinical research and logistics, medical communications, consulting, commercialization, and advanced technology products and services for pharmaceutical, biotechnology, and medical device industries worldwide, have an RSI of 66.77.

On August 21^st, 2017, PAREXEL and Osaka International Cancer Institute announced that they have formed an alliance to advance clinical development in Japan. The partnership will aim to drive greater efficiencies in support of patient recruitment for clinical trials in oncology and hematology, accelerating the development of innovative and effective new cancer treatments for patients. Register for free on DailyStockTracker.com and download the latest research report on PRXL at:
http://dailystocktracker.com/registration/?symbol=PRXL

--

Daily Stock Tracker: 

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

DST has not been compensated; directly or indirectly; for producing or publishing this document. 

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email contact@dailystocktracker.com . Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY 

DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 

NOT AN OFFERING 

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit:
http://dailystocktracker.com/disclaimer/

CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: contact@dailystocktracker.com
Phone number: (207)331-3313
Office Address: 377 Rivonia Boulevard, Rivonia, South Africa

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE dailystocktracker.com